Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE: Omaveloxolone in Pediatric Friedreich's Ataxia
NCT06953583Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of omaveloxolone in Friedreich ataxia (FA), sponsored by Biogen. Started Jun 2025; status: active, not recruiting.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT06953583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953583.